Literature DB >> 20232069

Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.

Anna Gomez1, Isidre Ferrer.   

Abstract

Previous studies have shown altered synuclein, increased oxidative stress damage and increased oxidative stress responses in patients with sporadic Parkinson's disease (PD) without cognitive impairment. Yet no information exists about possible molecular alterations in the cerebral cortex in familial PD. The present study shows abnormal alpha-synuclein solubility and aggregation, and aggregated nitrated alpha-synuclein, in the cerebral cortex (area 8) in cases with long-lasting PD linked with the G2019S LRRK2 mutation, one of them with a few Lewy bodies (LBs) and the other two without LBs in the cerebral cortex. Increased expression of the oxidative stress marker malondialdehyde-lysine (MDAL), together with increased oxidative stress responses, AGE receptors (RAGE) and superoxide dismutase 2, occurred in the frontal cortex in the three LRRK2 cases compared with three controls processed in parallel. Bi-dimensional gel electrophoresis, western blotting, in-gel digestion and mass spectrometry disclosed glial fibrillary acidic protein as a target of MDAL adducts. Tubulin beta4 and enolase 2 were also identified as targets of oxidative damage. These results demonstrate biochemical abnormalities of alpha-synuclein, and increased oxidative stress damage and oxidative stress responses in the frontal cortex in PD linked with G2019S LRRK2 mutation not related with the presence of cortical LBs and in the absence of apparent cognitive deficits. These findings show that the cerebral cortex in familial PD linked with G2019S LRRK2 is affected in a similar way than that seen in sporadic PD without cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20232069     DOI: 10.1007/s00401-010-0669-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  15 in total

1.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

2.  Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Andrew Ferree; Katelyn Smith; Eugenio Barone; Marzia Perluigi; Raffaella Coccia; William Pierce; Jian Cai; Cesare Mancuso; Rachel Squillace; Manfred Wiengele; Isabella Dalle-Donne; Benjamin Wolozin; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-03-20       Impact factor: 8.401

Review 3.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  Mov Disord       Date:  2017-11       Impact factor: 10.338

4.  Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Authors:  Lorraine V Kalia; Anthony E Lang; Lili-Naz Hazrati; Shinsuke Fujioka; Zbigniew K Wszolek; Dennis W Dickson; Owen A Ross; Vivianna M Van Deerlin; John Q Trojanowski; Howard I Hurtig; Roy N Alcalay; Karen S Marder; Lorraine N Clark; Carles Gaig; Eduardo Tolosa; Javier Ruiz-Martínez; Jose F Marti-Masso; Isidre Ferrer; Adolfo López de Munain; Samuel M Goldman; Birgitt Schüle; J William Langston; Jan O Aasly; Maria T Giordana; Vincenzo Bonifati; Andreas Puschmann; Margherita Canesi; Gianni Pezzoli; Andre Maues De Paula; Kazuko Hasegawa; Charles Duyckaerts; Alexis Brice; A Jon Stoessl; Connie Marras
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

5.  Clinical and pathological characteristics of LRRK2 G2019S patients with PD.

Authors:  Markos Poulopoulos; Etty Cortes; Jean-Paul G Vonsattel; Stanley Fahn; Cheryl Waters; Lucien J Cote; Carol Moskowitz; Lawrence S Honig; Lorraine N Clark; Karen S Marder; Roy N Alcalay
Journal:  J Mol Neurosci       Date:  2011-12-23       Impact factor: 3.444

Review 6.  The neuropathology of genetic Parkinson's disease.

Authors:  Markos Poulopoulos; Oren A Levy; Roy N Alcalay
Journal:  Mov Disord       Date:  2012-03-26       Impact factor: 10.338

Review 7.  Reimagining Alzheimer's disease--an age-based hypothesis.

Authors:  Karl Herrup
Journal:  J Neurosci       Date:  2010-12-15       Impact factor: 6.167

Review 8.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

9.  Alteration in glutathione content and associated enzyme activities in the synaptic terminals but not in the non-synaptic mitochondria from the frontal cortex of Parkinson's disease brains.

Authors:  G Harish; Anita Mahadevan; M M Srinivas Bharath; S K Shankar
Journal:  Neurochem Res       Date:  2012-10-16       Impact factor: 3.996

10.  Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease.

Authors:  Isidro Ferrer
Journal:  Parkinsons Dis       Date:  2011-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.